# Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP

> **NCT00565370** · PHASE1,PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 22 (actual)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **DRUG:** Capecitabine, Cisplatin, Sorafenib

## Key facts

- **NCT ID:** NCT00565370
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00565370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00565370, "Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00565370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*